FY2025 Earnings Forecast for AMLX Issued By Leerink Partnrs

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Research analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for Amylyx Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($1.35) for the year, up from their prior estimate of ($1.75). The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals' FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at ($1.00) EPS.

AMLX has been the subject of several other reports. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Baird R W upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Leerink Partners set a $4.00 price objective on shares of Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a research report on Friday, October 18th. Bank of America upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $4.20 to $10.00 in a research report on Wednesday, October 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Amylyx Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $7.33.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock traded up $0.14 during midday trading on Friday, reaching $3.65. 1,391,760 shares of the company's stock were exchanged, compared to its average volume of 873,081. Amylyx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $19.95. The firm has a market cap of $250.21 million, a price-to-earnings ratio of -0.96 and a beta of -0.53. The stock's 50-day simple moving average is $4.15 and its 200 day simple moving average is $3.62.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its stake in Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after purchasing an additional 4,883 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Amylyx Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company's stock worth $42,000 after buying an additional 5,104 shares in the last quarter. Algert Global LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth $47,000. Hsbc Holdings PLC increased its holdings in shares of Amylyx Pharmaceuticals by 57.9% during the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company's stock worth $150,000 after buying an additional 27,954 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth $156,000. 95.84% of the stock is currently owned by institutional investors.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the sale, the chief executive officer now directly owns 3,176,788 shares in the company, valued at $12,834,223.52. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.70% of the stock is currently owned by corporate insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.